| A Trial to Assess TEV-56286 at Different Doses in Healthy Participants (NCT07674940) | Teva Branded Pharmaceutical Products R&D LLC | 2026-06-26 |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (NCT07197866) | Teva Branded Pharmaceutical Products R&D LLC | 2025-09-30 |
| A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease (NCT06807463) | Teva Branded Pharmaceutical Products R&D LLC | 2025-03-31 |
| A Study to Assess New Formulations of TEV-56286 (NCT06911567) | Teva Branded Pharmaceutical Products R&D LLC | 2025-03-10 |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (NCT06664619) | Teva Branded Pharmaceutical Products R&D LLC | 2024-12-12 |
| A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo (NCT06625177) | Teva Branded Pharmaceutical Products R&D LLC | 2024-11-11 |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy (NCT06568237) | Teva Branded Pharmaceutical Products R&D LLC | 2024-10-02 |
| An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT06480552) | Teva Branded Pharmaceutical Products R&D LLC | 2024-07-22 |
| Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (NCT06253546) | Teva Branded Pharmaceutical Products R&D LLC | 2024-03-28 |
| Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder (NCT06319170) | Teva Branded Pharmaceutical Products R&D LLC | 2024-03-28 |
| An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (NCT06315283) | Teva Branded Pharmaceutical Products R&D LLC | 2024-03-20 |
| Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China (NCT07601516) | Teva Branded Pharmaceutical Products R&D LLC | 2024-02-02 |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (NCT06052267) | Teva Branded Pharmaceutical Products R&D LLC | 2023-08-30 |
| A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (NCT05693935) | Teva Branded Pharmaceutical Products R&D LLC | 2023-01-24 |
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (NCT05590377) | Teva Branded Pharmaceutical Products R&D LLC | 2023-01-23 |
| A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma (NCT05556616) | Teva Branded Pharmaceutical Products R&D LLC | 2023-01-12 |
| A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents (NCT04530110) | Teva Branded Pharmaceutical Products R&D LLC | 2020-09-16 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT04392648) | Teva Branded Pharmaceutical Products R&D LLC | 2020-06-24 |
| A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors (NCT04157517) | Teva Branded Pharmaceutical Products R&D LLC | 2019-12-12 |
| A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT03215030) | Teva Branded Pharmaceutical Products R&D LLC | 2017-10-04 |